Search

Your search keyword '"Haljasmägi L"' showing total 24 results

Search Constraints

Start Over You searched for: Author "Haljasmägi L" Remove constraint Author: "Haljasmägi L"
24 results on '"Haljasmägi L"'

Search Results

2. Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths

3. Autoantibodies against type I IFNs in patients with life-threatening COVID-19

4. Autoantibodies against type I IFNs in patients with life-threatening COVID-19

5. Auto-antibodies against type I IFNs in patients with life-threatening COVID-19

6. The risk of COVID-19 death is much greater and age-dependent with type I IFN autoantibodies

7. Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths

8. Autoantibodies Neutralizing Type III Interferons Are Uncommon in Patients with Severe Coronavirus Disease 2019 Pneumonia.

9. Inactive disease in patients with lupus is linked to autoantibodies to type I interferons that normalize blood IFNα and B cell subsets.

10. Protective antibodies and T cell responses to Omicron variant after the booster dose of BNT162b2 vaccine.

11. The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies.

12. Dynamics of antibody response to BNT162b2 vaccine after six months: a longitudinal prospective study.

13. Prevalence of SARS-CoV-2 IgG antibodies and their association with clinical symptoms of COVID-19 in Estonia (KoroSero-EST-1 study).

14. Autoantibodies neutralizing type I IFNs are present in ~ 4% of uninfected individuals over 70 years old and account for ~ 20% of COVID-19 deaths.

15. Differential levels of IFNα subtypes in autoimmunity and viral infection.

16. S95021, a novel selective and pan-neutralizing anti interferon alpha (IFN-α) monoclonal antibody as a candidate treatment for selected autoimmune rheumatic diseases.

17. Author Correction: A dynamic COVID-19 immune signature includes associations with poor prognosis.

18. Longitudinal proteomic profiling reveals increased early inflammation and sustained apoptosis proteins in severe COVID-19.

19. Evaluation of SARS-CoV-2 IgG antibody response in PCR positive patients: Comparison of nine tests in relation to clinical data.

20. Autoantibodies against type I IFNs in patients with life-threatening COVID-19.

21. A dynamic COVID-19 immune signature includes associations with poor prognosis.

22. LIPS method for the detection of SARS-CoV-2 antibodies to spike and nucleocapsid proteins.

23. IL-22 Paucity in APECED Is Associated With Mucosal and Microbial Alterations in Oral Cavity.

24. Monocytes present age-related changes in phospholipid concentration and decreased energy metabolism.

Catalog

Books, media, physical & digital resources